THAR - NASDAQ
Tharimmune, Inc.
$3.38
+0.86%Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
At a Glance
Live SnapshotTharimmune, Inc. Management Team
Mr. Mark Wendland
Chief Executive Officer
Dr. Nir Barak M.D.
Chief Medical Advisor
Mr. Vincent LoPriore
Executive Chairman of the Board
Dr. Sireesh Appajosyula Pharm.D.
Interim Chief Financial Officer & Director
Compensation
$620,921
Mr. Mark Toomey
President
Tharimmune, Inc. Insider Positioning
During the last 12 months, insiders have purchased $502K worth of THAR shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
339.5K
502.43K
0
0.00
+502K
+$502K
Top Buyers
Gravitas Capital Lp
Director, 10 Percent Owner, Officer: Executive Chairman
$500K
Parikh Sanam
Director
$1K
Appajosyula Sireesh
Director, Officer: Chief Executive Officer
$979
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $502K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
3 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
THAR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | January 16, 2026 | January 16, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | September 18, 2025 | September 18, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | April 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 21, 2024 | March 21, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | August 30, 2023 | August 30, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | June 17, 2022 | June 17, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.